

# PRESS RELEASE



## **SPL Medical announces long-term distribution agreement partnership for its novel contrast agent Ferrotran® (Ferumoxtran) for the Korean market**

Game-changing prostate cancer imaging agent market access in Korea.

**Nijmegen, Netherlands, 07.10.2021** – SPL Medical announced today that it has entered into an agreement for the distribution of its novel contrast agent Ferrotran® for the Korean market with Encormac Corp.

Nano particle-MRT with Ferrotran® can detect significantly smaller lymph node metastasis than with available methods, thus enabling for optimized patient care, because the direct treatment of the smallest lymph nodes is pivotal for the patients' survival chances.

Nano particle-MRT with Ferrotran® is available already now to patients within the running phase III trial, but as well in a named-patient-use program in Nijmegen, Netherlands and in a compassionate use program in Zurich, Switzerland.

“By the distribution agreement with Encormac Corp., a well-established and renown pharmaceutical distribution company with excellent market access to the South Korean radiology market sector, SPL medical is gaining market access for another top 10 major GDP (2020 figures) country market”, stated Dr. Jürgen Feuerstein, Chief Executive Officer of SPL medical.

“We are delighted to be in the position for efficient market access of Ferrotran® to the Korean radiology market, thus enabling optimised treatment of prostate cancer patients based on nano particle-MRI with Ferrotran® as a game-changing option for patient care,” concluded Hyun Ho Kim, president of Encormac Corp. “Ferrotran® will be a major innovation step in radiology in South Korea and the world due to its unique properties.

Ferrotran® (Ferumoxtran) is a novel contrast agent for use in MRI (magnetic resonance imaging) developed for the detection of lymph node metastases of prostate cancer. It is the first contrast agent for the use in MRI that is able to identify lymph node metastases as small as 2 mm. Being able to detect small metastases in prostate cancer early enough could enable a better chance of successful treatment.

SPL Medical is the manufacturer of Ferrotran® and responsible for the worldwide commercialization. The company has launched a multicenter phase III trial for Ferrotran® in major radiology / urology centers in Germany, Switzerland the Netherlands and Belgium, expecting to enroll a total of 180 patients with prostatic cancer.

Since 2014, more than 700 patients successfully underwent nano particle-MRI with Ferrotran® in various clinical trials, a named-patient use program at Radboud university medical center (Radboudumc) in Nijmegen, The Netherlands, and a compassionate use program in Switzerland at the University Hospital Zurich.

“nano particle-MRI by Ferrotran® represents a major opportunity to improve the diagnosis of lymph node metastases in prostate cancer patients, subsequently having potentially better treatment possibilities and fewer side effects,” stated Dr. Jürgen Feuerstein. “The compassionate use program at the Zurich University Hospital and the Radboudumc, Nijmegen named-patient program provide vital access for prostate cancer patients to this game-changing product. Meanwhile, at SPL medical, we will continue advancing our clinical development plan to enable potential registration of Ferrotran® and seeking for special access programs in further countries for bridging patient access to this technology beneficial for prostate cancer patient treatment.”

### **About Ferrotran®:**

Ferrotran® belongs to the group of USPIO's (Ultrasound Superparamagnetic Particles of Iron Oxide) and is the only contrast agent that can detect lymph node metastases as small as 2 mm. Standard MRI, CT or PET scans are normally not able to detect such small metastatic lymph nodes. Since the vast majority of prostate cancer patients are dying due to metastases, a precise diagnosis on this field is of utmost importance. The detection of small metastases, combined with a very clear contrast of the nano particle-MRI with the administration of Ferrotran®, giving also excellent visualization of vessels, enables an earlier and more precise treatment.

### **About SPL Medical:**

SPL Medical is a spin-off of the Radboud university medical center and is funded additionally by Oost NL, a Dutch regional venture capital company, and b.e.imaging GmbH, a German company specialized in the development and commercialization of contrast agents.

### **For more information about Ferrotran®, the clinical trials or SPL Medical:**

Dr. Juergen Feuerstein (CEO) at +49 171 173 5476 or  
For further information please visit: [www.ferrotran.com](http://www.ferrotran.com)

### **About Encormac Corp.:**

ENCORMAC is a diagnostics specialized pharmaceutical and innovative medical device company.  
ENCORMAC's first priority is to solve the problem of health issue and increase of medical expenses due to aging society.  
Therefore, we provide our enthusiasm and expertise to bring innovative products to the market with global partners.  
With passion and expertise, we provide the best information and services to the healthcare professionals to helping patients.

### **For more information about Encormac Corp.:**

Hyun Ho Kim (President) at +82 2 3143-5223  
For further information please visit: [www.encormac.com](http://www.encormac.com)